open access

Vol 15, No 1 (2020)
Report
Published online: 2020-02-27
Get Citation

Not only ISCHEMIA — report from AHA Scientific Sessions, Philadelphia, 16–18 November 2019

Tomasz Rechcinski, Jarosław D. Kasprzak
DOI: 10.5603/FC.2020.0011
·
Folia Cardiologica 2020;15(1):84-87.

open access

Vol 15, No 1 (2020)
Report
Published online: 2020-02-27

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

clinical trials, coronary artery disease, heart failure, risk factors

About this article
Title

Not only ISCHEMIA — report from AHA Scientific Sessions, Philadelphia, 16–18 November 2019

Journal

Folia Cardiologica

Issue

Vol 15, No 1 (2020)

Pages

84-87

Published online

2020-02-27

DOI

10.5603/FC.2020.0011

Bibliographic record

Folia Cardiologica 2020;15(1):84-87.

Keywords

clinical trials
coronary artery disease
heart failure
risk factors

Authors

Tomasz Rechcinski
Jarosław D. Kasprzak

References (6)
  1. Hochman JS, Reynolds HR, Bangalore S, et al. ISCHEMIA Research Group. Baseline characteristics and risk profiles of participants in the ISCHEMIA randomized clinical trial. JAMA Cardiol. 2019; 4(3): 273–286.
  2. Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020; 141(2): 90–99.
  3. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381(26): 2497–2505.
  4. German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020; 34(1): 1–9.
  5. Ray KK, Nicholls SJ, Ginsberg HD, et al. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019; 217: 72–83.
  6. Mehran R, Cao D, Baber U, et al. Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thromb Haemost. 2014; 112(5): 1069–1070.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl